Vertex Pharmaceuticals, Inc.

Nitromed, Inc.

Paratek Pharmaceuticals, Inc.

Tufts College

Upul Keerthi Bandarage

Tiansheng Wang

Francois Maltais

Paul S Charifson

Emanuele Perola

Michael P Clark

Mark Willem Ledeboer

Huai Gao

Brian Ledford

John P Duffy

Joseph M Kennedy

Ioana Davies

Luc J Farmer

Randy Scott Bethiel

Hongbo Deng

Wenxin Gu

Jon H Come

Robert J Davies

John J Court

Jingrong Cao

Michael John Boyd

David Messersmith

Francesco Gerald Salituro

David S Garvey

Chao Lin

Jinwang Xu

Joseph David Schroeder

Alex Aronov

Ronald Lee Grey, Jr

Xinqin Fang

M Woods Wannamaker

Dylan H Jacobs

Ursula A Germann

Kevin Michael Cottrell

Randal Byrn

Mark L Nelson

Dennis James Hurley

Arnaud Le Tiran

Stewart K Richardson

Yusheng Liao

Mohamed Y Ismail

Suganthini S Nanthakumar

Elaine B Krueger

Jian Jim Wang

Guy W Bemis

Esther Martinborough

Albert Charles Pierce

Michael Aaron Brodney

Jeremy Green

Robert B Perni

John Patrick Maxwell

Qing Tang

Anne-Laure Grillot

Simon Giroux

Adam R Looker

Michael J Arnost

James A Henderson

Ales Medek

Yi Shi

Stefanie Roeper

Nicole Zimmermann

Stephen Andrew Thomson

Hardwin O'Dowd

Lev Tyler Dewey Fanning

Philip N Collier

Kevin Gagnon

Mac Arthur Johnson, Jr

Craig Marhefka

Jeffrey O Saunders

L Gordon Letts

Steven M Ronkin

Glen Robert Rennie

Cheri A Stevenson

Govinda Rao Bhisetti

Roger Frechette

Sang William Tam

Darrell J Koza

Beena Bhatia

Subhash P Khanapure

Richard A Earl

Todd Bowser

Tadeusz Warchol

Kathy Stavropoulos

Maiko Ezawa

Peter Viski

Shiow-Jyi Wey

Muna Shrestha

Laura McIntyre

David J Lauffer

Pan Li

Juan-Miguel Jimenez

Andrew Miller

Lewis R Makings

Ramani R Ranatunge

Daniele M Bergeron

Michael Waldo

Miguel Garcia-Guzman Blanco

Gabriel Raffai

Akiko Nakatani

Ioana Drutu

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modulators of alpha-1 antitrypsin

Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K&#x3b3;. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Isoindolinone inhibitors of phosphatidylinositol 3-kinase

This invention provides methods of preparing 3-(pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridines and 3-(pyrimidin-2-yl)-1H-pyrazolo[3,4-b]pyridines, or pharmaceutically acceptable salts thereof that are useful for inhibiting the replication of influenza viruses in a biological sample or patient, reducing the amount of influenza viruses in a biological sample or patient, and treating influenza in a patient.

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Growing community of inventors

Lexington, MA, United States of America

Upul Keerthi Bandarage